Rabbit Polyclonal SSX2 Antibody

The SSX2 antibody targets the SSX2 protein, a member of the SSX (synovial sarcoma X breakpoint) family implicated in cancer biology. SSX genes, located on the X chromosome, encode cancer-testis (CT) antigens normally restricted to germ cells but aberrantly expressed in various malignancies, including synovial sarcoma, melanoma, and carcinomas. SSX2. specifically, is frequently involved in chromosomal translocations with SS18 (SYT) in synovial sarcoma, generating SS18-SSX fusion oncoproteins that drive tumorigenesis by disrupting epigenetic regulation and transcriptional programs. Antibodies against SSX2 are vital tools for detecting its expression in tumor tissues, aiding diagnosis (e.g., distinguishing synovial sarcoma from histologic mimics) and research into its oncogenic mechanisms. They also support studies exploring SSX2 as a therapeutic target, given its immunogenicity and tumor-specific expression. SSX2 antibodies are utilized in techniques like immunohistochemistry (IHC), Western blotting, and immunofluorescence to assess protein localization, expression levels, and interaction partners. Their development underscores the importance of CT antigens in tumor immunology and precision oncology. However, cross-reactivity with other SSX family members (e.g., SSX1. SSX4) may require validation via knockout controls. Research using SSX2 antibodies continues to elucidate its role in cancer progression and its potential in immunotherapy strategies, such as vaccines or adoptive T-cell therapies targeting SSX2-derived neoantigens.